ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 250 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 500 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup).benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 1000 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 2000 iu - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

ישראל - עברית - Ministry of Health

csl behring ltd., israel - coagulation factor ii (human); coagulation factor ix (human- rfixfc); coagulation factor vii (human); coagulation factor x (human); protein c; protein s antigen - אבקה וממס להכנת תמיסה להזרקה - coagulation factor ii (human) 200 - 480 iu; coagulation factor vii (human) 100 - 250 iu; coagulation factor ix (human- rfixfc) 200 - 310 iu; coagulation factor x (human) 220 - 600 iu; protein c 150 - 450 iu; protein s antigen 120 - 380 iu - coagulation factor ix, ii, vii and x in combination - coagulation factor ix, ii, vii and x in combination - -treatment and perioperative prophylaxis of bleedings in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin k antagonists, or in case of overdose of vitamin k antagonists, when rapid correction of the deficiency is required.

ישראל - עברית - Ministry of Health

genmedix , israel - coagulation factor ix (human) - אבקה וממס להכנת תמיסה להזרקה\אינפוזיה - coagulation factor ix (human) 1000 iu/vial - coagulation factor ix - coagulation factor ix - for the prevention and control of bleeding in factor ix deficiency, also known as hemophilia b or christmas disease.

ישראל - עברית - Ministry of Health

kamada ltd, israel - human plasma coagulation factor viii - אבקה להכנת תמיסה לזריקה - human plasma coagulation factor viii 50 iu/ml - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding: in patients with haemophilia a (congenital factor viii deficiency) in patient with acquired factor viii deficiency. haemoctin is not effective in controlling the bleeding of patients with von willebrond`s disease.

ישראל - עברית - Ministry of Health

kamada ltd, israel - human plasma coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - human plasma coagulation factor viii 50 iu/ml - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding: in patients with haemophilia a (congenital factor viii deficiency) in patient with acquired factor viii deficiency.haemoctin is not effective in controlling the bleeding of patients with von willebrond`s disease.

ישראל - עברית - Ministry of Health

kamada ltd, israel - human plasma coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - human plasma coagulation factor viii 100 iu/ml - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding: in patients with haemophilia a (congenital factor viii deficiency) in patient with acquired factor viii deficiency.haemoctin is not effective in controlling the bleeding of patients with von willebrond`s disease.